Yahoo Finance Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its First-Quarter Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Revenues beat expectations coming in atUS$93m, ahead of estimates by 8.5%. Statutory losses were somewhat smaller thanthe analysts expected, coming in at US$0.17 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Check out our latest analysis for BioCryst Pharmaceuticals
Taking into account the latest results, the consensus forecast from BioCryst Pharmaceuticals' ten analysts is for revenues of US$401.3m in 2024. This reflects a decent 13% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 40% to US$0.61. Before this latest report, the consensus had been expecting revenues of US$395.1m and US$0.63 per share in losses. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged.
There's been no major changes to the consensus price target of US$14.00, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic BioCryst Pharmaceuticals analyst has a price target of US$30.00 per share, while the most pessimistic values it at US$6.00. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.
Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that BioCryst Pharmaceuticals' revenue growth is expected to slow, with the forecast 18% annualised growth rate until the end of 2024 being well below the historical 51% p.a. growth over the last five years. Compare this to the 577 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 18% per year. So it's pretty clear that, while BioCryst Pharmaceuticals' revenue growth is expected to slow, it's expected to grow roughly in line with the industry.
The Bottom Line
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple BioCryst Pharmaceuticals analysts - going out to 2026, and you can see them free on our platform here.
It is also worth noting that we have found 2 warning signs for BioCryst Pharmaceuticals (1 can't be ignored!) that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
